International technology group Schott held a groundbreaking ceremony for a greenfield pharmaceutical glass tubing plant in Jinyun, Zhejiang.
The pharmaceutical sector plays a key role within China’s roadmap, which is moving from manufacturing generics to new drug development.
This shift is underlined by the Healthy China 2030 initiative. There is a high demand for premium pharmaceutical packaging made out of Type I pharmaceutical glass in the domestic market.
The demand for high quality drug packaging products is underlined through government initiatives and patient safety standards.
The new plant will enable Schott to participate in the advancement of the Chinese pharmaceutical packaging industry.
Schott will invest €60 million in the first phase to install a yearly capacity of up to 20,000 tonnes with production scheduled to start at the end of 2020.
The new plant will supply the Chinese domestic pharmaceutical packaging market to aid its development.
The plant will manufacture Fiolax glass tubing, which is a 5.0 middle borosilicate glass. The manufacturing site will support the move away from the low borosilicate glass (so called 7.0 glass type) to the higher quality middle borosilicate glass (so called 5.0 glass type), which is already well established globally.
